Adjuvant imatinib mesylate therapy improves recurrence-free survival
نویسندگان
چکیده
منابع مشابه
The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
BACKGROUND Extra-abdominal desmoid tumors are rare neoplasms with variable biological behavior. The mainstay of treatment is surgery. Complementary treatment with tyrosine-kinase receptor inhibitor drugs, particularly imatinib mesylate, has been reported in the literature. The purpose of this study was to determine the possible presence of tyrosine-kinase receptors in extra-abdominal desmoid tu...
متن کاملMetachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor in gastrointestinal tracts; however, the synchronous or metachronous coexistence of GIST with additional primary malignancy is not common.Here, we present an unusual case of gastric GIST with metachronous primary lung adenocarcinoma diagnosed during his adjuvant treatment with oral receptor tyrosine kinase inhibitor imat...
متن کاملImatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib.
Vol. 27, No. 5, 2015 641 Received August 9, 2014, Revised November 10, 2014, Accepted for publication February 4, 2015 Corresponding author: Eun Joo Park, Department of Dermatology, Hallym University Sacred Heart Hospital, 22 Gwanpyeong-ro 170 beon-gil, Dongan-gu, Anyang 14068, Korea. Tel: 82-31-380-3765, Fax: 82-31-386-3761, E-mail: [email protected] This is an Open Access article distrib...
متن کاملImatinib Mesylate: A Molecularly Targeted Therapy for Gastrointestinal Stromal Tumors
Although their overall incidence is uncommon, gastrointestinal stromal tumors (GIST) are the most frequently encountered mesenchymal tumors of the GI tract. Their pathology has been recently defined by the presence of KIT (transmembrane receptor tyrosine kinase). The majority of GISTs have c-kit gain-of-function mutations mainly in exon 11 (highly conserved juxtamembrane region) that eventuates...
متن کاملDoes imatinib mesylate therapy cause growth hormone deficiency?
OBJECTIVE The purpose of this study was to determine whether or not imatinib mesylate therapy induces growth hormone deficiency (GHD). SUBJECTS AND METHODS Seventeen patients with chronic myloid leukemia (CML) were enrolled in the study. The glucagon stimulation test (GST), and standard deviation scores (SDSs) of insulin-like growth fac- tor 1 (IGF-I) and insulin-like growth factor binding pr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Gastroenterology & Hepatology
سال: 2009
ISSN: 1759-5045,1759-5053
DOI: 10.1038/nrgastro.2009.80